Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health solutions for the animal health industry in the United States and internationally. The company commercializes products primarily across companion animals comprising dogs, cats, and horses; and species, including livestock, such as cattle, swine, poultry, fish, and sheep. It also offers parasiticides, vaccines, dermatology, anti-infectives, pain and sedation, other pharmaceutical, and animal health diagnostics. In addition, the company provides animal health diagnostics, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, which include nutritionals, as well as products and services in biodevices, genetic tests, and precision animal health. It markets its products to veterinarians, livestock producers, and pet owners. The company has collaborated with Blacksmith Medicines, Inc. to discover and develop novel antibiotics for animal health. Zoetis Inc. was incorporated in 2012 and is headquartered in Parsippany, New Jersey.

Revenue projections:

ZTS's revenues are expected to fall below last year's, and this forecast tends to raise concerns among investors. A revenue drop can negatively impact the company's profitability, making investors more cautious about their positions due to the risks of declining financial performance.

Financial Ratios:

currentRatio	3.084000
forwardPE	12.149355
debtToEquity	293.996000
earningsGrowth	0.012000
revenueGrowth	-0.002000
grossMargins	0.717380
operatingMargins	0.407210
trailingEps	6.080000
forwardEps	6.533680

ZTS's current ratio, being 3.084, means the company is well-positioned to meet its short-term debt obligations. This reflects ZTS's strong liquidity, as its cash reserves and current assets provide more than enough coverage for its immediate liabilities.
Zoetis Inc.'s Forward PE ratio is favorable, indicating that the stock price is well-positioned in relation to its earnings. It is not overpriced, leaving room for growth, which makes it a solid option for investors seeking both stability and future appreciation.
Zoetis Inc.'s elevated debt-to-equity ratio reflects a high level of debt relative to equity, signaling that the company is heavily leveraged. This reliance on debt could increase financial risk in periods of economic uncertainty.
ZTS's low earnings and revenue growth point to a potential decline in profits. This signals a downturn in financial performance, suggesting that the company might face challenges in maintaining its current level of profitability.
Positive gross and operating margins for Zoetis Inc. demonstrate the company's profitability. These margins reflect strong financial performance, with efficient operations contributing to the company's ability to generate consistent profits.
With a forward EPS greater than its trailing EPS, ZTS is expected to see higher profitability this year. The forecasted increase in earnings reflects optimism about the company's financial growth and potential for improved performance over the prior year.

Price projections:

The current valuation of ZTS against its projections does not reveal significant risks or opportunities. This neutral assessment implies a stable market, where investors may prefer to maintain their positions until future trends become clearer.

Insider Transactions:

There were 1 transactions selling ZTS stock, with prevailing market price of 125.55999755859375.ZTS stock was bought in 2 transactions, while the market price was at 75.50499725341797.With more buys than sells around ZTS's current price, there seems to be increased confidence among investors. This shift may indicate a favorable outlook, as the buying behavior suggests optimism for the stock's future growth or resilience.

Recommendation changes over time:

A recent buy bias from analysts toward Zoetis Inc. indicates strong confidence in the stock's future performance. This could encourage investors to park their money in Zoetis Inc., viewing it as a stable and potentially rewarding investment opportunity with promising long-term growth prospects.